To verify whether the identified differential genes are aberrantly expressed in breast cancer cells and the impact on the prognosis of breast cancer patients, we examined the expression of pivotal genes in clinical samples from GEPIA and performed survival analysis of the above-mentioned pivotal genes, as well as for different stages of breast cancer disease progression, and identified TP53, ACLY, PPARG and JUN as potential candidate genes significantly associated with Chidamide treatment of breast cancer. This evidence concerns the gene TP53 and breast cancer.